T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

Abstract

Many viruses, including retroviruses, are characterized by their specific cell tropism. Lymphadenopathy-associated virus (LAV) is a human lymphotropic retrovirus isolated from patients with acquired immune deficiency syndrome (AIDS) or related syndromes, that displays selective tropism for a subset of T lymphocytes defined by the expression of a surface glycoprotein of relative molecular mass 62,000 (62K) termed T4 (refs 6-8). This glycoprotein delineates a subset of T lymphocytes with mainly helper/inducer functions, while T lymphocytes of the reciprocal subset express a glycoprotein termed T8, have mainly cytotoxic/suppressor activities, and are unable to replicate LAV. Such a tropism may be controlled at the genomic level by regulatory sequences, as described for the human T-cell leukaemia viruses HTLV-I and -II (refs 2, 3). Alternatively or concomitantly, productive cell infection may be controlled at the membrane level, requiring the interaction of a specific cellular receptor with the virus envelope, as demonstrated recently for Epstein-Barr virus (EBV). Therefore, we have investigated whether the T4 molecule itself is related to the receptor for LAV. We report here that preincubation of T4+ lymphocytes with three individual monoclonal antibodies directed at the T4 glycoprotein blocked cell infection by LAV. This blocking effect was specific, as other monoclonal antibodies--such as antibody to histocompatibility locus antigen (HLA) class II or anti-T-cell natural killer (TNK) target--directed at other surface structures strongly expressed on activated cultured T4+ cells, did not prevent LAV infection. Direct virus neutralization by monoclonal antibodies was also ruled out. These results strongly support the view that a surface molecule directly involved in cellular functions acts as, or is related to, the receptor for a human retrovirus.

Extended binding sites of cyclophilin as revealed by the interaction with HIV‐1 Gag polyprotein derived oligopeptides

“…Previous reports have shown the lower incidence of developing AIDS for HIV + patients who received immunosuppressive therapy with cyclosporin A (CsA) after organ transplantation [1][2][3]. Moreover, in response to the immunosuppressive drugs CsA and FK506, the growth of cells chronically infected with HIV-1 and HIV-2 was selectively inhibited [4].…”

Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120

“…In addition to the functional spikes, there is also evidence for the presence of nonfunctional derivatives, such as gp41 stumps and gp120/gp41 monomers, on the viral surface (54,66). Most variants of HIV-1 enter cells through attachment of the envelope spike to the main cellular receptor CD4 (15,39), which triggers a conformational change allowing interaction with a cellular coreceptor, typically CCR5 or CXCR4 (53), eventually leading to fusion of virus and cell membranes. Potent entry inhibitors can target various stages of this process (51).…”

HIV/AIDS: 30 Years of progress and future challenges

“…The identification of CD4 as the major virus receptor was very important, particularly as few virus receptors were known then [12]. Early studies revealed differences among HIV isolates to replicate in macrophages versus T-cell lines that correlated with their cytopathology (e.g.…”